Enabling Innovative Translational Research in Acute Kidney Injury

Clinical and Translational Science

Volumn 5, Issue 1, 2012, Pages 93-101

  Zarjou, Abolfazl ^a   Sanders, Paul W ^a,b   Mehta, Ravindra L ^c   Agarwal, Anupam ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Kidney; Nephrology; Translational research

Indexed keywords

ALKALINE PHOSPHATASE; AMINOPHYLLINE; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CISPLATIN; CURCUMIN; CYSTATIN C; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FATTY ACID BINDING PROTEIN; FENOLDOPAM; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 18; KETANSERIN; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT SOMATOMEDIN C; TROPONIN;

ACUTE KIDNEY FAILURE; APOPTOSIS; CLINICAL RESEARCH; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DIALYSIS; ERYTHROCYTE TRANSFUSION; EX VIVO STUDY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEALTH PROMOTION; HEALTH SERVICES RESEARCH; HEART SURGERY; HUMAN; HYDROSTATIC PRESSURE; IMMUNOMODULATION; IN VIVO STUDY; INTENSIVE CARE; ISCHEMIC PRECONDITIONING; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY PROXIMAL TUBULE; LONGITUDINAL STUDY; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MORTALITY; MULTICENTER STUDY (TOPIC); NEPHRECTOMY; NONHUMAN; OLIGURIA; OUTCOMES RESEARCH; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; TRANSLATIONAL RESEARCH; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; DIFFUSION OF INNOVATION; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FUNCTION TESTS; NEPHROLOGY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84857659502     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00302.x     Document Type: Review

References (101)

1. Rondon-Berrios H, Palevsky PM. Treatment of acute kidney injury: an update on the management of renal replacement therapy. Curr Opin Nephrol Hypertens. 2007; 16(2): 64-70.
2. Himmelfarb J, Ikizler TA. Acute kidney injury: changing lexicography, definitions, and epidemiology. Kidney Int. 2007; 71 (10): 971-976.
3. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif. 2010; 29(3): 300-307.
4. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008; 109(4): c182-c187.
5. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11(2): R31. Available at:.
6. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008; 73(5): 538-546.
7. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008; 36(Suppl 4): S146-151.
8. Zappitelli M. Epidemiology and diagnosis of acute kidney injury. Semin Nephrol. 2008; 28(5) 436-446.
9. Uchino S. The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 2006; 12(6): 538-543.
10. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006; 17(4): 1135-1142.
11. Goldberg R, Dennen P. Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis. 2008; 15(3): 297-307.
12. Rosner MH. The pathogenesis of susceptibility to acute kidney injury in the elderly. Curr Aging Sci. 2009; 2(2): 158-164.
13. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010; 17(4): 302-307.
14. Kaufman J, Dhakal M, Patel B, Hamburger R. Community-acquired acute renal failure. Am J Kidney Dis. 1991; 17(2): 191-198.
15. Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients. Nephrol Dial Transplant. 2006; 21 (5): 1248-1252.
16. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294(7): 813-818.
17. McCarthy JT. Prognosis of patients with acute renal failure in the intensive-care unit: a tale of two eras. Mayo Clin Proc. 1996; 71(2): 117-126.
18. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000; 26(7): 915-921.
19. Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml W. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002; 30(9): 2051-2058.
20. Coca SG, Peixoto AJ, Garg AX, Krumholz HM, Parikh CR. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis. 2007; 50(5): 712-720.
21. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005; 16(11): 3365-3370.
22. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003; 14(6): 1549-1558.
23. Zerhouni EA. Translational research: moving discovery to practice. Clin Pharmacol Ther. 2007; 81(1): 126-128.
24. Woolf SH. The meaning of translational research and why it matters. JAMA. 2008; 299(2): 211-213.
25. Westfall JM, Mold J, Fagnan L. Practice-based research-"Blue Highways" on the NIH roadmap. JAMA. 2007; 297(4): 403-406.
26. Feldman AM. The clinical and translational science "tent". Clin Transl Sci. 2010; 3(1): 1.
27. Edelstein CL. Biomarkers of acute kidney injury. Adv Chronic Kidney Dis. 2008; 15(3): 222-234.
28. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008; 73(9): 1008-1016.
29. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif. 2010; 29(4): 357-365.
30. Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med. 2008; 36(Sup-pl4):S159-S165.
31. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med. 2010; 8: 34.
32. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis. 1986; 8(5): 332-337.
33. Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Phar-macokinet. 1979; 4(3): 200-222.
34. Herrera J, Rodriguez-lturbe B. Stimulation of tubular secretion of creatinine in health and in conditions associated with reduced nephron mass. Evidence for a tubular functional reserve. Nephrol Dial Transplant. 1998; 13(3): 623-629.
35. Siew ED, Matheny ME, Ikizler TA, Lewis JB, Miller RA, Waitman LR, Go AS, Parikh CR, Peterson JF. Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int. 2010; 77(6): 536-542.
36. Bagshaw SM, Gibney RT. Conventional markers of kidney function. Crit Care Med. 2008; 36(Suppl 4): S152-S158.
37. American Society of Nephrology Renal Research Report. J Am Soc Nephrol. 2005; 16(7): 1886-1903.
38. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton). 2010; 15(4): 419-428.
39. Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A, Calandra S, Noto P, Le Moli C, Alongi B, et al. Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur Rev Med Pharmacol Sci. 2009; 13(3): 197-200.
40. Ronco C. N-GAL: diagnosing AKI as soon as possible. Crit Care. 2007; 11 (6): 173. Available at:.
41. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M, Yu W, Forster CS, Gong G, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med. 2011; 17(2): 216-222.
42. Przybylowski P, Malyszko J, Malyszko JS. Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in heart allograft recipients. Transplant Proc. 2010; 42(5): 1797-1802.
43. Moore E, Bellomo R, Nichol A. Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiol. 2010; 76(6): 425-440.
44. Portal AJ, McPhail MJ, Bruce M, Coltart I, Slack A, Sherwood R, Heaton ND, Shawcross D, Wendon JA, Heneghan MA. Neutrophil gelatinase-associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transpl. 2010; 16(11): 1257-1266.
45. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Salmela KT. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int. 2010; 79: 89-98.
46. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. Shedding of kidney injury mole-cule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem. 2002; 277(42): 39739-39748.
47. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007; 212(2): 209-217.
48. Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl. 2008; 241: 78-83.
49. Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H. Kidney injury molecule-1 in renal disease. J Pathol. 2010; 220(1): 7-16.
50. Huo W, Zhang K, Nie Z, Li Q, Jin F. Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury. Transplant Rev (Orlando). 2010; 24(3): 143-146.
51. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 2010; 77(11): 1020-1030.
52. Lattanzio MR, Kopyt NP. Acute kidney injury: new concepts in definition, diagnosis, pathophy-siology, and treatment. J Am Osteopath Assoc. 2009; 109(1): 13-19.
53. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008; 359(1): 7-20.
54. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 2008; 19(6): 1233-1238.
55. Palevsky PM. Renal support in acute kidney injury-how much is enough? N Engl J Med. 2009; 361(17): 1699-1701.
56. de Francisco AL, Pinera C. Challenges and future of renal replacement therapy. Hemodial Int. 2006; 10(Suppl 1):S19-S23.
57. Jacobs C. Renal replacement therapy by hemodialysis: an overview. Nephrol Ther. 2009; 5(4): 306-312.
58. Lameire N, Van Biesen W, Vanholder R. Did 20 years of technological innovations in hemodialysis contribute to better patient outcomes? Clin J Am Soc Nephrol. 2009; 4(Suppl 1): S30-S40.
59. Schiffl H. Daily haemodialysis in acute renal failure. Old wine in a new bottle? Minerva Urol Nefrol. 2004; 56(3): 265-277.
60. Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF. Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol. 1999; 17(5): 451-455.
61. Humes HD, MacKay SM, Funke AJ, Buffington DA. Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int. 1999; 55(6): 2502-2514.
62. Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM, Humes HD. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif. 2002; 20(1): 55-60.
63. Ding F, Humes HD. The bioartificial kidney and bioengineered membranes in acute kidney injury. Nephron Exp Nephrol. 2008; 109(4): el18-el22.
64. De Vriese AS, Bourgeois M. Pharmacologic treatment of acute renal failure in sepsis. Curr Opin Crit Care. 2003; 9(6): 474-480.
65. Pelte CH, Chawla LS. Novel therapeutic targets for prevention and therapy of sepsis associated acute kidney injury. Curr Drug Targets. 2009; 10(12): 1205-1211.
66. Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. Lancet. 2004; 363(9422): 1721-1723.
67. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344(10): 699-709.
68. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288(7): 862-871.
69. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000; 356(9248): 2139-2143.
70. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005; 142(7): 510-524.
71. Knepper MA, Lankford SP, Terada Y. Renal tubular actions of ANF. Can J Physiol Pharmacol. 1991; 69(10): 1537-1545.
72. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database Syst Rev. 2009(4):CD006028.
73. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4(2): 261-272.
74. Goes N, Urmson J, Vincent D, Ramassar V, Halloran PF. Effect of recombinant human insulinlike growth factor-1 on the inflammatory response to acute renal injury. J Am Soc Nephrol. 1996; 7(5): 710-720.
75. Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999; 55(6): 2423-2432.
76. Imai N, Kaur T, Rosenberg ME, Gupta S. Cellular therapy of kidney diseases. Semin Dial. 2009; 22(6): 629-635.
77. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med. 2008; 59:311-325.
78. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol. 2008; 36(6): 733-741.
79. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther. 2010; 1 (5): 34.
80. Schafer R, Northoff H. Cardioprotection and cardiac regeneration by mesenchymal stem cells. Panminerva Med. 2008; 50(1): 31-39.
81. Iyer SS, Co C, Rojas M. Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med. 2009; 51(1): 5-16.
82. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009; 15(1): 42-49.
83. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 2005; 289(1): F31-F42.
84. Zarjou A, Kim J, Traylor AM, Sanders PW, Balla J, Agarwal A, Curtis LM. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Renal Physiol. 2010; 300: 254-262.
85. Hill-Kapturczak N, Chang SH, Agarwal A. Heme oxygenase and the kidney. DNA Cell Biol. 2002; 21 (4): 307-321.
86. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 2006; 70(3): 432-443.
87. Maines MD. New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda). 2005; 20: 382-389.
88. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol. 2010; 50: 323-354.
89. Jarmi T, Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep. 2009; 11(1): 56-62.
90. Ozaki KS, Marques GM, Nogueira E, Feitoza RQ, Cenedeze MA, Franco MF, Mazzali M, Soares MP, Pacheco-Silva A, Camara NO. Improved renal function after kidney transplantation is associated with heme oxygenase-1 polymorphism. Clin Transplant. 2008; 22(5): 609-616.
91. Lin CC, Yang WC, Lin SJ, Chen TW, Lee WS, Chang CF, Lee PC, Lee SD, Su TS, Fann CS, et al. Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int. 2006; 69(1): 165-172.
92. Liu KD, Glidden DV. Clinical trials for acute kidney injury: design challenges and possible solutions. Curr Drug Targets. 2009; 10(12): 1190-1195.
93. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol. 2007; 2(2): 356-365.
94. Marchewka Z, Kuzniar J, Dlugosz A. Enzymuria and beta2-mikroglobulinuria in the assessment of the influence of proteinuria on the progression of glomerulopathies. Int Urol Nephrol. 2001; 33(4): 673-676.
95. Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB. Biomarkers of acute renal injury and renal failure. Shock. 2006; 26(3): 245-253.
96. Devarajan P. Proteomics for the investigation of acute kidney injury. Contrib Nephrol. 2008; 160: 1-16.
97. Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'Amico G, Goldsmith D, Devarajan P, Bellomo R. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2010; 36(3): 452-461.
98. Nakamura T, Sugaya T, Koide H. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock. 2009; 31 (5): 454-459.
99. Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta. 2006; 374(1-2): 1-7.
100. Basnakian AG. Netrin-1: a potential universal biomarker for acute kidney injury. Am J Physiol Renal Physiol. 2008; 294(4): F729-F730.
101. Reeves WB, Kwon O, Ramesh G. Netrin-1 and kidney injury. II. Netrin-1 is an early biomarker of acute kidney injury. Am J Physiol Renal Physiol. 2008; 294(4): F731-F738.